Evaluation of NovoRapid infusion as a treatment option in the management of diabetic ketoacidosis

Intern Med J. 2017 Nov;47(11):1317-1320. doi: 10.1111/imj.13607.

Abstract

This study evaluates the clinical efficacy and safety of NovoRapid (insulin aspart) compared to Actrapid™ (human neutral insulin) for diabetic ketoacidosis (DKA). In this retrospective study involving 40 patients, no statistically significant differences were observed between biochemical variables, infusion duration or complications in patients treated with insulin aspart or human neutral insulin. These results support the use of insulin aspart as an effective and safe alternative to human neutral insulin in DKA.

Keywords: diabetic ketoacidosis; infusions, intravenous; insulin; insulin aspart; insulin, short acting.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Cohort Studies
  • Diabetic Ketoacidosis / blood
  • Diabetic Ketoacidosis / diagnosis
  • Diabetic Ketoacidosis / drug therapy*
  • Disease Management*
  • Female
  • Humans
  • Hypoglycemic Agents / administration & dosage*
  • Infusions, Intravenous
  • Insulin Aspart / administration & dosage*
  • Insulin, Regular, Pork / administration & dosage
  • Male
  • Middle Aged
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin, Regular, Pork
  • insulin, neutral
  • Insulin Aspart